Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under investor pressure for transparency regarding their obesity drug CagriSema, after trial results disappointed. Patients report weight loss but side effects like nausea. Investors ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.